 |
|
| Type | Private |
|---|---|
| Founded | 1874 |
| Headquarters | Zürich, Switzerland |
| Area served | Europe |
| Key people | H. Björklund (CEO) Toni Weitzberg (Chairman) |
| Industry | Pharmaceuticals |
| Revenue | ▲ EUR 3,400 million (2006) |
| Employees | 12,400 (2007) |
| Parent | Nordic Capital CSFB Alternative Capital |
| Website | www.nycomed.com |
Nycomed is a European pharmaceutical company. Nycomed is privately owned primarily by the two private equity investors Nordic Capital and CSFB Alternative Capital. Production is located in Norway, Denmark, Poland, Finland, Austria, Belgium, Germany, India, and Estonia. Head office is located in Zürich, Switzerland. Total revenue was € 3,400 million (2006) and the group had 12,000 employees.
Contents |
History
The company was started in Norway in 1874, as an agent of foreign pharmaceutical products. The founder was pharmacist M.Nyegaard. The company name was Nyegaard & Co. from 1890 until 1986 when it was changed to Nycomed. In 1913 it started producing generic drugs, among these Globoid (copy of Aspirin). In 1969, the revolutionary radiocontrast agent Amipaque was discovered, starting a long process of internationalisation. The next generation product Omnipaque made the company highly successful. In 1986, Nycomed was purchased by the power company Hafslund. In 1994, the diagnostic division of US based Sterling Winthrop was acquired. Then, in 1996, the therapeutics division Nycomed Pharma was demerged whilst the diagnostic division Nycomed Imaging was merged with the British company Amersham plc. In 1999, the therapeutics company was established under the name Nycomed as an independent company. In 2007, Nycomed took over the much larger German pharmaceutical company, Altana Pharma. This acquisition made Nycomed one of the world's 25 largest pharmaceutical companies. In 2007 Nycomed acquired American company Bradley pharmaceuticals. A 2008 closing deal is expected in February.
Nycomed has pursued a strategy of licensing new medicines from research companies and introducing them to Europe. The company provides specialist/hospital products (e.g. Tachosil) throughout Europe. General Practitioner and pharmacy medicines are also provided but in selected countries. Today the company is active throughout Europe and continues to expand into new markets.
In October 2008, Nycomed Canada Inc. was named one of "Canada's Top 100 Employers" by Mediacorp Canada Inc., and was featured in Maclean's newsmagazine. Later that month, Nycomed Canada was also named one of Greater Toronto's Top Employers, which was announced by the Toronto Star newspaper.[1]
Collaborative Research
In addition to internal research and development activities Nycomed is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.[2][3]
References
- ^ "Reasons for Selection, 2009 Canada's Top 100 Employers Competition". http://www.eluta.ca/top-employer-nycomed.
- ^ Mattes WB (2008), Public consortium efforts in toxicogenomics, Methods Mol Biol. 2008;460:221-38 [1]
- ^ "InnoMed PredTox Member Organizations". http://www.innomed-predtox.com/consortium/members/. Retrieved 2008-08-25.
External links
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
